Alkaloid AD SkopjeXMAE:ALK +0.21%88 ROE % is 13.38% as of Mar. 2026, which is 19% above its 10-year median of 11.29. GuruFocus rates XMAE:ALK with a GF Score™ of 88/100 and a GF Value™ of MKD27,166.15 (Modestly Undervalued). Among 936 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 71.26% on this metric.
The historical rank and industry rank for Alkaloid AD Skopje's ROE % or its related term are showing as below:
XMAE:ALK'
s ROE % Range Over the Past 10 Years
Min: 8.89 Med: 11.29 Max: 12.2
Current: 12.2
During the past 13 years, Alkaloid AD Skopje's highest ROE % was 12.20%. The lowest was 8.89%. And the median was 11.29%.
XMAE:ALK's ROE % is ranked better than 71.26% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs XMAE:ALK: 12.20
Alkaloid AD Skopje (XMAE:ALK) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Alkaloid AD Skopje ROE % Related Terms
Alkaloid AD Skopje ROE % Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's ROE % distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Alkaloid AD Skopje (XMAE:ALK) has a ROE % of 13.38% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Alkaloid AD Skopje and its competitors. This is 19% above median its historical median of 11.29. Over the past decade, Alkaloid AD Skopje's ROE % has ranged from 8.89 to 12.20. According to the industry distribution chart, Alkaloid AD Skopje ranks #269 out of 936 companies in the Drug Manufacturers industry, placing it in the top 28.7%.
Is Alkaloid AD Skopje's ROE % too high?
Alkaloid AD Skopje's current ROE % of 13.38% is 19% above median its 10-year median of 11.29. Over the past 10 years, this metric has ranged from a low of 8.89 to a high of 12.20. The Drug Manufacturers industry median ROE % is 5.87. Alkaloid AD Skopje's value of 13.38% is 128.1% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #269 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #269 out of 936 companies for ROE %. This puts Alkaloid AD Skopje in the upper half of its industry. The industry median ROE % is 5.87. Alkaloid AD Skopje's value of 13.38% is 128.1% above this benchmark. Historically, Alkaloid AD Skopje's own ROE % has ranged from 8.89 to 12.20 over the past decade. While the company's 10-year median is 11.29 vs. the industry median of 5.87, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current ROE % of 13.38% is 128.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current ROE % is 13.38%, which is 19% above median its own 10-year median of 11.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,166.15, compared to a current price of MKD24,300.00 — trading 10.6% below its estimated fair value. The current ROE % is 13.38%, which is 19% above median its 10-year median of 11.29 and 128.1% above the Drug Manufacturers industry median of 5.87. Alkaloid AD Skopje's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current ROE % is 13.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD24,300.00 is trading 10.6% below its estimated GF Value™ of MKD27,166.15.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
ROE %: 13.38% (19% above median its 10-year median of 11.29)
GF Value™: MKD27,166.15 vs. price of MKD24,300.00 (10.6% below fair value)
Industry Position: 128.1% above the Drug Manufacturers median (#269 of 936)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
88GF Score
Get the complete analysis for XMAE:ALK
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
